Send us a text

The Surfers explore the impact that NASHmap, the first Machine Learning model that can identify patients likely to have NASH, can have on clinical trials and patient treatment.

Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Optum de-identified EHR dataset. The model includes 14 variables, some obvious, others less so, that produce an AUC of 0.82 in the NIDDK database and 0.79 in the Optum database. This conversation explores NASHmap's powerful implications for future clinical trial recruitment and large-scale patient screening.

Send us a text

The Surfers analyze outputs from NASHmap, the first Machine Learning model that can identify patients likely to have NASH, to learn what we can about the disease and how to think about its value for racial and ethnic minorities.

Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Optum de-identified EHR dataset. The model includes 14 variables, some obvious, others less so, that produce an AUC of 0.82 in the NIDDK database and 0.79 in the Optum database. This conversation explores some model elements and statistical outputs to glean knowledge about what the model says about NASH itself.

Send us a text

Jörn Schattenberg discusses NASHmap, the first Machine Learning model that can identify patients likely to have NASH in clinical settings. Louise, Roger and guest Dr. Kris Kowdley join Jörn to discuss the model from academic, patient treatment and statistical perspectives.

Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Optum de-identified EHR dataset. The model includes 14 variables, some obvious, others less so, that produce an AUC of 0.82 in the NIDDK database and 0.79 in the Optum database. The episode focuses on how the model was built and what it implies for clinical trial recruitment, patient care and the view it provides of NASH risk factors. This has powerful implications for future clinical trial recruitment and large-scale patient screening. 

Send us a text

Jörn Schattenberg discusses the issues that drove the project to develop a Machine Learning model that can identify patients likely to have NASH in clinical settings, and discusses key elements of study and model design.

Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Optum de-identified EHR dataset. The model includes 14 variables, some obvious, others less so, that produce an AUC of 0.82 in the NIDDK database and 0.79 in the Optum database. This conversation focuses on why the collaborators undertook this project and how the model was built.

Send us a text

Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review pharmacotherapy themes to be covered at the 4th Global NASH Congress.

Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review drug-related topics covered at the Congress. This conversation discusses issues ranging from modes of action that attack fructose metabolism to the importance of hearing regulators at meetings like this one. Listen to get a feel for what commercial, financial and R & D actors can hear about by attending the event on April 28 and 29.

Send us a text

Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review holistic and patient-centric issues to be covered at the 4th Global NASH Congress.

Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review patient-centric topics covered at the Congress. This conversation discusses the increasing imoportance of phenotyping in diagnosing and prescribing for individual patients after drugs are available. Listen to get a feel for what commercial, financial and R & D actors can hear about by attending the event on April 28 and 29.

Send us a text

Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review non-invasive testing themes to be covered at the 4th Global NASH Congress.

Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review non-invasive testing topics covered at the Congress. This conversation discusses advances in technology and the need for non-invasive tests that provide stronger positive predictive value. Listen to get a feel for what commercial, financial and R & D actors can hear about by attending the event on April 28 and 29.

Send us a text

Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to survey the agenda for the 4th Global NASH Congress.

The 4th Global NASH Congress has presentations of interest on a broad array of topics. Congress Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for this event. Along with Jörn Schattenberg, they review the topics of interest at the Congress and highlight some papers and topics that SurfingNASH will cover in its end-of-day episodes on April 28 and 29. Listen to get a feel for what makes this a worthwhile Congress for commercial, financial and R & D actors needing to stay up-to-date on the latest trends and insights.

Send us a text

Roger Green conducts one-on-one interviews with Stephen Harrison and Alina Allen to explore specific issues regarding new issues and insights for clinical research and drug development resulting from the work of Dr. Allen and her colleagues.

Stephen Harrison discusses the important contribution this paper makes to our knowledge about disease progression. He then suggests several types of studies and issues that are likely to progress from this research and closes by focusing on its immense value for cirrhotic patients and medications. Alina Allen discusses her vision of how both research and treatment might evolve as researchers learn more about the interplay of different types of diagnostic testing in both research and clinical settings.

Send us a text

The group focuses on the patient treatment implications of being able to identify the patients who are at risk of rapid progression, particularly among those with compensated cirrhosis.

Louise Campbell and Alina Allen discuss the psychological and practical aspects of treating patients (particularly those with cirrhosis) who know they are risk of imminent disease progression, while Roger Green asks whether this kind of predictive power might drive Compassionate Use protocols for agents that have not yet been approved. The question, "Who Will Be the Larry Kramer of NASH?" comes into this discussion as well.